Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri DSMZ 17648 (PYLOSHOT) for Helicobacter pylori eradication
IRCT20200106046021N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Jan 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of saccharomyces boulardii in Helicobacter-associated gastritis and Helicobacter pylori infection (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Helicobacter pylori eradication rate and Treatment side effects. Started Jan 2020; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
Helicobacter-associated gastritisHelicobacter pylori infection
Beyond the preview
Go deeper on IRCT20200106046021N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200106046021N1.